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We have read with great interest the article
‘Expert consensus for multi-modality imaging
evaluation of cardiovascular complications of
radiotherapy in adults: a report from the
European Association of Cardiovascular Imaging
and the American Societyof Echocardiography’
by Lancellotti et al.1 Late cardiovascular compli-
cations after chest radiotherapy (RT), even
modern RT techniques, are a remarkably in-
creasing problem. Care of cancer survivors is
becoming an emergent and topic issue especial-
ly after chest irradiation and more so for left
breast cancer patients.2 In this subset of
patients, RT should be addressed a risk factor
for coronary artery disease (CAD) and since
vascular endothelium seems to be the first
target of radiation, it should be our duty to
detect early marker of endothelial damage
long before clinical coronary events. In our in-
stitution, we are enrolling early left breast
cancer patients in a protocol study to estimate
coronaryflowreserve (CFR)by99mTc-sestamibi
SPECT Myocardial Perfusion Imaging before and
after RT. Regional CFR is defined as the ratio
between dipyridamole and baseline myocardial
blood flow.3 In preliminary data, we have found
STsegmentandTwaveofventricular repolariza-
tion abnormalities registered soon after RT,
coupled with myocardial perfusion defects
(mostly in the apical region of the left ventricle)
and with reduction of estimated values of CFR
even in patients with no other risk factors for
(CAD) besides chest RT. Our patients were all
treated according to the Quantec constraints.4
We do not know yet the predicting role of
CFR reduction for clinical coronary events, but
while following up very closely our patients, we
are aggressively treating their risk factors for
CAD.
We are also intrigued by the genetic issue of
RT-induced cardiotoxicity, and we are also
trying to identify the genetic marker of
increased risk. We have read the editorial by
Kelsey et al.5 and the paper by Hilbers et al.6
about the association between genetic variants
in Transforming Growth Factor b-1 and Plas-
minogen activator inhibitor-1 and an increased
risk for cardiovascular diseases after RT for
breast cancer. The authors say that, for the
great majority of individuals, the normal tissue
toxicity is influenced by the cumulative effect
of multiple genetic polymorphisms. If these as-
sumption are proved to be true, then we will be
able to predict which patient are more exposed
to toxicity and we can improve our ‘tailored
therapies’ maximizing the therapeutic ratio of
cancer therapies.
We would like to ask two questions:
(1) What is your opinion on genetic determi-
nants of RT-induced toxicity? The search
for polymorphisms should be encouraged
in Oncology Departments to modify
therapeutic strategies. (For example, left
mastectomy instead of breast-conserving
surgery plus adjuvant RT if the risk of
RT-induced cardiotoxicity is genetically
increased.)
(2) Do you think it is worthy to search for
a suitable early marker of endothelial
damage? And do you think CFR reduction
could be such a preclinical marker? Would
you suggest an ECG recording soon after
RT to screen high-risk patients?
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We thank Dr Gallucci for her letter about the
joint EACVI/ASE expert consensus for multi-
modality imaging evaluation of cardiovascular
complications of radiotherapy in adults.1 As
underlined, there is compelling evidence that
chest radiotherapy can increase the risk of
heart disease. Although modern radiotherapy
techniques are likely to reduce the prevalence
and severity of radiation-induced heart disease
(RIHD), the incidence of RIHD is expected to
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increase in cancer survivors who have received
old radiotherapy regimens.
The pathophysiology of RIHD remains
poorly understood. Genetic and exogenous
factors certainly enhance the risk of RIHD and
contribute to inter-patient disease expression
differences.2 As exogenous factors have been
shown to result in genomic instability, and as
low-dose radiation induces long-lasting genomic
instability, synergistic interaction between
radiation-induced effects and pathogenic events
unrelated to radiation exposure is highly prob-
able.Whennormal tissuesare irradiated, identify-
ing factorsmodulating their sensitivity toradiation
is paramount but challenging. Little is known
about the genetic variants of RIHD. Recently,
single-nucleotide polymorphisms in a series of
genes associated with DNA repair pathways,
damage response, and angiogenesis regulating
pathways have been identified. As an example,
TGFb1 29C.T polymorphism, which is asso-
ciated with a lower TGFb1 serum level, has
been shown to be associated with a two-fold
increase in cardiovascular disease risk in breast
cancer survivors who were irradiated.3 Although
these data are very promising, recommendations
on the systematic assessment of these genetic
polymorphisms cannot yet be drawn. Also, it
would be premature at this time to use these
preliminary results to modify the treatment
strategies. Further confirmations are needed.
However, building a bio-bank of blood samples
for further targeted genetic analysis makes
sense. Several exogenous factors potentiate
the risk of RIHD. Younger age, cardiovascular
risk factors (i.e. smoking and hypertension) or
pre-existing cardiovascular disease, exposure to
high doses of radiation (.30 Gy), concomitant
chemotherapy, anterior or left chest irradiation
location, and absence of shielding are the most
common risk factors associated with RIHD.
In the present letter, Dr Gallucci elegantly
pointed out that the ‘primum movens’ of
RIHD relates to radiation-induced endothelial
dysfunction. When coronary arteries are in
the field of radiation, induced endothelial dys-
function may be translated into impaired cor-
onary flow reserve (CFR). Several imaging
methods, including MIBI SPECT-MPI (single-
photon emission computed tomography myo-
cardial perfusion imaging), can be used to iden-
tify reduced CFR.4 Dr Gallucci also reported
her preliminary data regarding an ongoing
study in which CFR was assessed before and
after radiotherapy in patients with left breast
cancers. After treatment, a set of abnormalities
(ST-T changes, myocardial perfusion defects in
the left ventricular apical region, and reduction in
estimated values of CFR) was found even in
patients with no other risk factors for coronary
artery disease other than chest irradiation.
However, as the monitoring data are still
ongoing, the impact of a reduced CFR on the
outcome was not reported. In the meantime,
these patients have been followed up closely
and treatedaggressively to correct any risk factor.
Even with technical improvements in radio-
therapy delivery, a high incidence of left ven-
tricular perfusion defects is found early after
tangential radiotherapy for breast cancer.5,6
However, little is known about the time
course and evolution of these perfusion abnor-
malities. In addition, whether these radiation-
induced heart SPECT defects might persist or
be the premises of later effects is still unknown.
Microvascular disease, endothelial dysfunction,
vascular spasm, or coronary artery disease
might all contribute at various degrees to these
perfusion abnormalities. Similar mechanisms
contribute to stress-induced perfusion defects
and reduced CFR during the provocative test.
Therefore, they do not necessarily correspond
to a typical coronary territory. So far, the clinical
significance of these perfusion abnormalities
remains unclear. So, although of potential inter-
est, it is premature to consider the systematic
evaluation of CFR as a preclinical marker of
endothelial damage after thoracic radiotherapy.
ECG represents the traditional support and
completion to the clinical examination, but
ECG ST-T abnormalities are often non-specific
in cancer survivors. Moreover, in the short
term, these ECG changes are often reversible
and seem to be functionally insignificant.7
The adequate strategy for screening of RIHD
remains a source of debate in the medical com-
munity. The lack of strong evidence has led the
EACVI/ASE Writing Committee to suggest
consensus statements rather than strict guide-
lines. Large prospective studies are thus
required to confirm the clinical utility of non-
invasive imaging for comprehensive screening
and surveillance of asymptomatic cancer survi-
vors. Other unsolved issues would deserve
specific actions: collection of standardized inci-
dence data, trials to evaluate preventive mea-
sures, genomic testing to explain variability of
incidence and onset, investigation of the impact
on new agents that might share common signal-
ling pathways with those involved in cardiac
damage, and management of interventional
strategies to reduce the burden of cardiovascu-
lar complications by acting simultaneously on
multiple risk factors.
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